Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

MRC funded study into early anti-retroviral treatment for children in Africa

Medical Research Council : 04 November, 2013  (Company News)
Children affected by HIV in Africal could increase survival chances with earlier anti-retroviral treatment according to a new study
MRC funded study into early anti-retroviral treatment for children in Africa


In a study funded by the Medical Research Council (MRC), the Engineering and Physical Sciences Research Council (EPSRC), the Department for International Development (DFID) and Great Ormond Street Hospital (GOSH) Biomedical Research Centre, researchers have shown that starting children with HIV in Africa on antiretroviral treatments before the age of six increases their likelihood of not just surviving into adulthood, but surviving with a stronger immune system. These results provide important information to help in the development of international guidelines on HIV treatment for children.



The team, led by Joanna Lewis from UCL in collaboration with UK, Ugandan and Zimbabwean investigators, analysed immunological data from a clinical trial called ARROW which looked at 1,206 children in Africa with HIV given anti-retroviral treatment (ART). They found that children started on ART under the age of six develop a stronger immune system than children who start treatment at an older age, probably in part because young children have a very active thymus, a key organ for the immune system.



They also found that, as a result of immune system damage and declining thymic activity, for each year that goes by after the age of six, the capacity for the immune system to recover declines. If therapy is delayed until after 10 years of age, children are unlikely to make as strong an immune recovery as when they are younger. This is particularly important for doctors looking to mitigate effectively the damage to a child’s immune system and optimise recovery.



The ARROW trial, which was coordinated by the MRC Clinical Trials Unit at UCL, looked at questions around how best to treat children with HIV in Africa. It followed 1,206 children in Uganda and Zimbabwe for five years. The team used data from the trial to develop a mathematical model where children’s CD4 white blood cell count (a critical measure in the immune system) in combination with their age can predict their corresponding CD4 count as an adult.



Dr Joanna Lewis at UCL, who led the study, said: “It is becoming increasingly clear that how we manage all aspects of the care of children with HIV will determine the quality of their lives as adults. This study provides an important steer as to when anti-retroviral therapy needs to be started to optimise immune recovery required for long-term health and quality of life.”



Professor Robin Callard, one of the senior authors, said: “Developing this model has provided important insights into the way children respond to ART and will identify other factors that could be important in determining the quality of immune recovery as children grow up.”



Professor Nigel Klein, a senior author on the paper and paediatrician looking after children with HIV at Great Ormond Street Hospital, said: “The success of anti-retroviral therapy means that we now expect most children who start on therapy to survive into adulthood. This work marks a change in our thinking from treatment guidelines based upon reducing the short-term risk of dying to optimising the quality of the immune system when children become adults. This work has already altered the management of children in our hospital.”


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo